NCT07169825 Evaluation of Targeted Radionuclide Therapy of Lu-177 PSMA in Patients With Compromised Renal and/or Bone Marrow Function
| NCT ID | NCT07169825 |
| Status | Recruiting |
| Phase | Phase 4 |
| Sponsor | M.D. Anderson Cancer Center |
| Condition | Lu-177 PSMA |
| Study Type | INTERVENTIONAL |
| Enrollment | 25 participants |
| Start Date | 2026-03-30 |
| Primary Completion | 2026-09-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 4 studies follow an already-approved treatment in real-world conditions to monitor long-term safety and effectiveness.
This trial targets 25 participants in total. It began in 2026-03-30 with a primary completion date of 2026-09-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
To determine the dose of Pluvicto therapy absorbed in the tumors and organs of patients whose kidneys and/or bone marrow are not working properly.
Eligibility Criteria
Eligibility Criteria * Participants that are approved for Pluvicto therapy and have been identified to have renal complications or compromised marrow function. Renal complication is defined as GFR: 30-50ml/min, creatinine: ULN-twofold ULN; while compromised marrow function is indicated by total WBC 2.5 x 109 L - LLN, or platelet count 75-100 x 109 L. * Participants who agree to be imaged multiple times as defined in the study protocol. Exclusion Criteria * Pluvicto therapy patients without renal or marrow function complications * Participants who do not wish to be imaged multiple times as per the study protocol. * Women and children since this is treatment for prostate cancer.
Contact & Investigator
Guofan Xu, MD
PRINCIPAL INVESTIGATOR
M.D. Anderson Cancer Center
Frequently Asked Questions
Who can join the NCT07169825 clinical trial?
This trial is open to male participants only, studying Lu-177 PSMA. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT07169825 trial and what does that mean for participants?
Phase 4 studies are conducted after a treatment has been approved. They monitor long-term safety and real-world effectiveness in a broader patient population.
Is NCT07169825 currently recruiting?
Yes, NCT07169825 is actively recruiting participants. Contact the research team at gxu2@mdanderson.org for enrollment information.
Where is the NCT07169825 trial being conducted?
This trial is being conducted at Houston, United States.
Who is sponsoring the NCT07169825 clinical trial?
NCT07169825 is sponsored by M.D. Anderson Cancer Center. The principal investigator is Guofan Xu, MD at M.D. Anderson Cancer Center. The trial plans to enroll 25 participants.